TY - JOUR
T1 - Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension
T2 - Results from an International Prospective Registry
AU - Delcroix, Marion
AU - Lang, Irene
AU - Pepke-Zaba, Joanna
AU - Jansa, Pavel
AU - D'Armini, Andrea M.
AU - Snijder, Repke
AU - Bresser, Paul
AU - Torbicki, Adam
AU - Mellemkjaer, Sören
AU - Lewczuk, Jerzy
AU - Simkova, Iveta
AU - Barberà, Joan A.
AU - De Perrot, Marc
AU - Hoeper, Marius M.
AU - Gaine, Sean
AU - Speich, Rudolf
AU - Gomez-Sanchez, Miguel A.
AU - Kovacs, Gabor
AU - Jais, Xavier
AU - Ambroz, David
AU - Treacy, Carmen
AU - Morsolini, Marco
AU - Jenkins, David
AU - Lindner, Jaroslav
AU - Dartevelle, Philippe
AU - Mayer, Eckhard
AU - Simonneau, Gérald
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Chronic thromboembolic pulmonary hypertension, a rare complication of acute pulmonary embolism, is characterized by fibrothrombotic obstructions of large pulmonary arteries combined with small-vessel arteriopathy. It can be cured by pulmonary endarterectomy, and can be clinically improved by medical therapy in inoperable patients. A European registry was set up in 27 centers to evaluate long-term outcome and outcome correlates in 2 distinct populations of operated and not-operated patients who have chronic thromboembolic pulmonary hypertension. Methods and Results-A total of 679 patients newly diagnosed with chronic thromboembolic pulmonary hypertension were prospectively included over a 24-month period. Estimated survival at 1, 2, and 3 years was 93% (95% confidence interval [CI], 90-95), 91% (95% CI, 87-93), and 89% (95% CI, 86-92) in operated patients (n=404), and only 88% (95% CI, 83-91), 79% (95% CI, 74-83), and 70% (95% CI, 64-76) in not-operated patients (n=275). In both operated and not-operated patients, pulmonary arterial hypertension-targeted therapy did not affect survival estimates significantly. Mortality was associated with New York Heart Association functional class IV (hazard ratio [HR], 4.16; 95% CI, 1.49-11.62; P=0.0065 and HR, 4.76; 95% CI, 1.76-12.88; P=0.0021), increased right atrial pressure (HR, 1.34; 95% CI, 0.95-1.90; P=0.0992 and HR, 1.50; 95% CI, 1.20-1.88; P=0.0004), and a history of cancer (HR, 3.02; 95% CI, 1.36-6.69; P=0.0065 and HR, 2.15; 95% CI, 1.18-3.94; P=0.0129) in operated and not-operated patients, respectively. Additional correlates of mortality were bridging therapy with pulmonary arterial hypertension-targeted drugs, postoperative pulmonary hypertension, surgical complications, and additional cardiac procedures in operated patients, and comorbidities such as coronary disease, left heart failure, and chronic obstructive pulmonary disease in not-operated patients. Conclusions-The long-term prognosis of operated patients currently is excellent and better than the outcome of notoperated patients.
AB - Chronic thromboembolic pulmonary hypertension, a rare complication of acute pulmonary embolism, is characterized by fibrothrombotic obstructions of large pulmonary arteries combined with small-vessel arteriopathy. It can be cured by pulmonary endarterectomy, and can be clinically improved by medical therapy in inoperable patients. A European registry was set up in 27 centers to evaluate long-term outcome and outcome correlates in 2 distinct populations of operated and not-operated patients who have chronic thromboembolic pulmonary hypertension. Methods and Results-A total of 679 patients newly diagnosed with chronic thromboembolic pulmonary hypertension were prospectively included over a 24-month period. Estimated survival at 1, 2, and 3 years was 93% (95% confidence interval [CI], 90-95), 91% (95% CI, 87-93), and 89% (95% CI, 86-92) in operated patients (n=404), and only 88% (95% CI, 83-91), 79% (95% CI, 74-83), and 70% (95% CI, 64-76) in not-operated patients (n=275). In both operated and not-operated patients, pulmonary arterial hypertension-targeted therapy did not affect survival estimates significantly. Mortality was associated with New York Heart Association functional class IV (hazard ratio [HR], 4.16; 95% CI, 1.49-11.62; P=0.0065 and HR, 4.76; 95% CI, 1.76-12.88; P=0.0021), increased right atrial pressure (HR, 1.34; 95% CI, 0.95-1.90; P=0.0992 and HR, 1.50; 95% CI, 1.20-1.88; P=0.0004), and a history of cancer (HR, 3.02; 95% CI, 1.36-6.69; P=0.0065 and HR, 2.15; 95% CI, 1.18-3.94; P=0.0129) in operated and not-operated patients, respectively. Additional correlates of mortality were bridging therapy with pulmonary arterial hypertension-targeted drugs, postoperative pulmonary hypertension, surgical complications, and additional cardiac procedures in operated patients, and comorbidities such as coronary disease, left heart failure, and chronic obstructive pulmonary disease in not-operated patients. Conclusions-The long-term prognosis of operated patients currently is excellent and better than the outcome of notoperated patients.
KW - Endarterectomy
KW - hypertension, pulmonary
KW - pulmonary embolism
KW - survival
KW - thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84959480777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959480777&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.115.016522
DO - 10.1161/CIRCULATIONAHA.115.016522
M3 - Article
C2 - 26826181
AN - SCOPUS:84959480777
VL - 133
SP - 859
EP - 871
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 9
ER -